drugset / Trial / NCT05858515
REVERSE-Long COVID-19 With Baricitinib Study
Phase 3
Withdrawn
Vanderbilt University Medical Center
Emory University · collabUniversity of California, San Francisco · collabUniversity of Minnesota · collabVanderbilt University · collabYale University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.
Timeline
- Start
- 2024-10-21
- Primary completion
- 2027-12-31
- Completion
- 2029-12-30
Outcome
Outcome not reported
Stopped (Enrollment): “This submission for the pilot study has been withdrawn as the full trial opened under a different NCT number before participants enrolled in the pilot.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 1 mg | — |
| Subject | Baricitinib | Small molecule | 2 mg | — |
| Subject | Baricitinib | Small molecule | 4 mg | — |